Article

POS-320 EFFECTIVENESS AND SAFETY OF RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH OBESITY, TYPE TWO DIABETES AND CKD

Sherzod AbdullaevRepublican Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Immunogenetics, Tashkent, UzbekistanRanokhon IgamberdievaTashkent pediatric medical institute, Internal medicine, Tashkent, Uzbekistan

Kidney International Reportsjournal2022en

ABI

Abstract

We aimed to evaluate the clinical characteristics and outcomes of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concurrent obesity, type two diabetes (T2D) and chronic kidney disease (CKD)

Topics

Atrial Fibrillation Management and Outcomes

Identifiers

DOI: 10.1016/j.ekir.2022.01.341

Citations and references

Cited by 00 references

Metrics — AkademScholar · Coming soon